Remodeling Neurodegeneration: Somatic Cell Reprogramming-Based Models of Adult Neurological Disorders

Neuron

Volumn 78, Issue 6, 2013, Pages 957-969

  Qiang, Liang ^a   Fujita, Ryousuke ^a   Abeliovich, Asa ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL FATE; ENVIRONMENTAL STRESS; EPIGENETICS; HUMAN; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; PERSONALIZED MEDICINE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SOMATIC CELL;

ADULT; ANIMALS; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NEURAL STEM CELLS; NEURODEGENERATIVE DISEASES;

EID: 84879255268     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2013.06.002     Document Type: Review

References (121)

1. Abeliovich A., Doege C.A. Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease. Neuron 2009, 61:337-339.
2. Almeida S., Zhang Z., Coppola G., Mao W., Futai K., Karydas A., Geschwind M.D., Tartaglia M.C., Gao F., Gianni D., et al. Induced pluripotent stem cell models of progranulin-deficient frontotemporal dementia uncover specific reversible neuronal defects. Cell Rep. 2012, 2:789-798.
3. Ambasudhan R., Talantova M., Coleman R., Yuan X., Zhu S., Lipton S.A., Ding S. Direct reprogramming of adult human fibroblasts to functional neurons under defined conditions. Cell Stem Cell 2011, 9:113-118.
4. Amoroso M.W., Croft G.F., Williams D.J., O'Keeffe S., Carrasco M.A., Davis A.R., Roybon L., Oakley D.H., Maniatis T., Henderson C.E., Wichterle H. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J.Neurosci. 2013, 33:574-586.
5. An M.C., Zhang N., Scott G., Montoro D., Wittkop T., Mooney S., Melov S., Ellerby L.M. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012, 11:253-263.
6. Ash P.E., Bieniek K.F., Gendron T.F., Caulfield T., Lin W.L., Dejesus-Hernandez M., van Blitterswijk M.M., Jansen-West K., Paul J.W., Rademakers R., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77:639-646.
7. Ban H., Nishishita N., Fusaki N., Tabata T., Saeki K., Shikamura M., Takada N., Inoue M., Hasegawa M., Kawamata S., Nishikawa S. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc. Natl. Acad. Sci. USA 2011, 108:14234-14239.
8. Bettens K., Sleegers K., Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol. 2013, 12:92-104.
9. Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., Carrasco M., Phatnani H.P., Puddifoot C.A., Story D., Fletcher J., et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. USA 2012, 109:5803-5808.
10. Bock C., Kiskinis E., Verstappen G., Gu H., Boulting G., Smith Z.D., Ziller M., Croft G.F., Amoroso M.W., Oakley D.H., et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011, 144:439-452.
11. Boillée S., Cleveland D.W. Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1. J.Clin. Invest. 2008, 118:474-478.
12. Boulting G.L., Kiskinis E., Croft G.F., Amoroso M.W., Oakley D.H., Wainger B.J., Williams D.J., Kahler D.J., Yamaki M., Davidow L., et al. A functionally characterized test set of human induced pluripotent stem cells. Nat. Biotechnol. 2011, 29:279-286.
13. Brennand K.J., Simone A., Jou J., Gelboin-Burkhart C., Tran N., Sangar S., Li Y., Mu Y., Chen G., Yu D., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011, 473:221-225.
14. Byers B., Cord B., Nguyen H.N., Schüle B., Fenno L., Lee P.C., Deisseroth K., Langston J.W., Pera R.R., Palmer T.D. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS ONE 2011, 6:e26159.
15. Caiazzo M., Dell'Anno M.T., Dvoretskova E., Lazarevic D., Taverna S., Leo D., Sotnikova T.D., Menegon A., Roncaglia P., Colciago G., et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011, 476:224-227.
16. Casarosa S., Fode C., Guillemot F. Mash1 regulates neurogenesis in the ventral telencephalon. Development 1999, 126:525-534.
17. Chambers S.M., Fasano C.A., Papapetrou E.P., Tomishima M., Sadelain M., Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 2009, 27:275-280.
18. Chambers S.M., Qi Y., Mica Y., Lee G., Zhang X.J., Niu L., Bilsland J., Cao L., Stevens E., Whiting P., et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nat. Biotechnol. 2012, 30:715-720.
19. Chatrchyan S., Khachatryan V., Sirunyan A.M., Tumasyan A., Adam W., Bergauer T., Dragicevic M., Erö J., Fabjan C., Friedl M., et al. Measurement of the t-channel single top quark production cross section in pp collisions at √s=7 TeV. Phys. Rev. Lett. 2011, 107:091802. CMS Collaboration.
20. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-823.
21. Cooper O., Seo H., Andrabi S., Guardia-Laguarta C., Graziotto J., Sundberg M., McLean J.R., Carrillo-Reid L., Xie Z., Osborn T., et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci. Transl. Med. 2012, 4. 141ra190.
22. Corti S., Nizzardo M., Simone C., Falcone M., Nardini M., Ronchi D., Donadoni C., Salani S., Riboldi G., Magri F., et al. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci. Transl. Med. 2012, 4. 165ra162.
23. Da Cruz S., Cleveland D.W. Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 2011, 21:904-919.
24. Davila J., Chanda S., Ang C.E., Südhof T.C., Wernig M. Acute reduction in oxygen tension enhances the induction of neurons from human fibroblasts. J.Neurosci. Methods 2013, 216:104-109.
25. Dawson T.M., Ko H.S., Dawson V.L. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
26. De Strooper B., Iwatsubo T., Wolfe M.S. Presenilins and γ-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006304.
27. Di Giorgio F.P., Carrasco M.A., Siao M.C., Maniatis T., Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 2007, 10:608-614.
28. Di Giorgio F.P., Boulting G.L., Bobrowicz S., Eggan K.C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008, 3:637-648.
29. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321:1218-1221.
30. Ding Q., Lee Y.K., Schaefer E.A., Peters D.T., Veres A., Kim K., Kuperwasser N., Motola D.L., Meissner T.B., Hendriks W.T., et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013, 12:238-251.
31. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., Svendsen C.N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-280.
32. Egawa N., Kitaoka S., Tsukita K., Naitoh M., Takahashi K., Yamamoto T., Adachi F., Kondo T., Okita K., Asaka I., et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012, 4. 145ra104.
33. Eroglu C., Barres B.A. Regulation of synaptic connectivity by glia. Nature 2010, 468:223-231.
34. Fasano C.A., Chambers S.M., Lee G., Tomishima M.J., Studer L. Efficient derivation of functional floor plate tissue from human embryonic stem cells. Cell Stem Cell 2010, 6:336-347.
35. Ferraiuolo L., Kirby J., Grierson A.J., Sendtner M., Shaw P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011, 7:616-630.
36. Gore A., Li Z., Fung H.L., Young J.E., Agarwal S., Antosiewicz-Bourget J., Canto I., Giorgetti A., Israel M.A., Kiskinis E., et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011, 471:63-67.
37. Greber B., Coulon P., Zhang M., Moritz S., Frank S., Müller-Molina A.J., Araúzo-Bravo M.J., Han D.W., Pape H.C., Schöler H.R. FGF signalling inhibits neural induction in human embryonic stem cells. EMBO J. 2011, 30:4874-4884.
38. Han D.W., Tapia N., Hermann A., Hemmer K., Höing S., Araúzo-Bravo M.J., Zaehres H., Wu G., Frank S., Moritz S., et al. Direct reprogramming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 2012, 10:465-472.
39. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
40. Hobert O. Regulatory logic of neuronal diversity: terminal selector genes and selector motifs. Proc. Natl. Acad. Sci. USA 2008, 105:20067-20071.
41. Hockemeyer D., Wang H., Kiani S., Lai C.S., Gao Q., Cassady J.P., Cost G.J., Zhang L., Santiago Y., Miller J.C., et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 2011, 29:731-734.
42. Hussein S.M., Batada N.N., Vuoristo S., Ching R.W., Autio R., Närvä E., Ng S., Sourour M., Hämäläinen R., Olsson C., et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011, 471:58-62.
43. Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 2012, 482:216-220.
44. Jiang H., Ren Y., Yuen E.Y., Zhong P., Ghaedi M., Hu Z., Azabdaftari G., Nakaso K., Yan Z., Feng J. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat. Commun. 2012, 3:668.
45. Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013, 16:571-579.
46. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10:698-712.
47. Khachatryan V., Sirunyan A.M., Tumasyan A., Adam W., Bergauer T., Dragicevic M., Erö J., Fabjan C., Friedl M., Frühwirth R., et al. Search for pair production of second-generation scalar leptoquarks in pp collisions at √s = 7 TeV. Phys. Rev. Lett. 2011, 106:201803. CMS Collaboration.
48. Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., Ko S., Yang E., Cha K.Y., Lanza R., Kim K.S. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4:472-476.
49. Kim K., Doi A., Wen B., Ng K., Zhao R., Cahan P., Kim J., Aryee M.J., Ji H., Ehrlich L.I., et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467:285-290.
50. Kim J., Efe J.A., Zhu S., Talantova M., Yuan X., Wang S., Lipton S.A., Zhang K., Ding S. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc. Natl. Acad. Sci. USA 2011, 108:7838-7843.
51. Kim J., Su S.C., Wang H., Cheng A.W., Cassady J.P., Lodato M.A., Lengner C.J., Chung C.Y., Dawlaty M.M., Tsai L.H., Jaenisch R. Functional integration of dopaminergic neurons directly converted from mouse fibroblasts. Cell Stem Cell 2011, 9:413-419.
52. Kim K., Zhao R., Doi A., Ng K., Unternaehrer J., Cahan P., Huo H., Loh Y.H., Aryee M.J., Lensch M.W., et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat. Biotechnol. 2011, 29:1117-1119.
53. Kim K.Y., Hysolli E., Park I.H. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc. Natl. Acad. Sci. USA 2011, 108:14169-14174.
54. Kirkeby A., Grealish S., Wolf D.A., Nelander J., Wood J., Lundblad M., Lindvall O., Parmar M. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 2012, 1:703-714.
55. Koch P., Opitz T., Steinbeck J.A., Ladewig J., Brüstle O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for invitro instruction and synaptic integration. Proc. Natl. Acad. Sci. USA 2009, 106:3225-3230.
56. Kondo T., Asai M., Tsukita K., Kutoku Y., Ohsawa Y., Sunada Y., Imamura K., Egawa N., Yahata N., Okita K., et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 2013, 12:487-496.
57. Kriks S., Shim J.W., Piao J., Ganat Y.M., Wakeman D.R., Xie Z., Carrillo-Reid L., Auyeung G., Antonacci C., Buch A., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011, 480:547-551.
58. Ladewig J., Mertens J., Kesavan J., Doerr J., Poppe D., Glaue F., Herms S., Wernet P., Kögler G., Müller F.J., et al. Small molecules enable highly efficient neuronal conversion of human fibroblasts. Nat. Methods 2012, 9:575-578.
59. Lafaille F.G., Pessach I.M., Zhang S.Y., Ciancanelli M.J., Herman M., Abhyankar A., Ying S.W., Keros S., Goldstein P.A., Mostoslavsky G., et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012, 491:769-773.
60. Laurent L.C., Ulitsky I., Slavin I., Tran H., Schork A., Morey R., Lynch C., Harness J.V., Lee S., Barrero M.J., et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011, 8:106-118.
61. Lee G., Studer L. Modelling familial dysautonomia in human induced pluripotent stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2011, 366:2286-2296.
62. Lee G., Kim H., Elkabetz Y., Al Shamy G., Panagiotakos G., Barberi T., Tabar V., Studer L. Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells. Nat. Biotechnol. 2007, 25:1468-1475.
63. Li W., Sun W., Zhang Y., Wei W., Ambasudhan R., Xia P., Talantova M., Lin T., Kim J., Wang X., et al. Rapid induction and long-term self-renewal of primitive neural precursors from human embryonic stem cells by small molecule inhibitors. Proc. Natl. Acad. Sci. USA 2011, 108:8299-8304.
64. Liu H., Zhang S.C. Specification of neuronal and glial subtypes from human pluripotent stem cells. Cell. Mol. Life Sci. 2011, 68:3995-4008.
65. Liu G.H., Qu J., Suzuki K., Nivet E., Li M., Montserrat N., Yi F., Xu X., Ruiz S., Zhang W., et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 2012, 491:603-607.
66. Lo L., Dormand E., Greenwood A., Anderson D.J. Comparison of the generic neuronal differentiation and neuron subtype specification functions of mammalian achaete-scute and atonal homologs in cultured neural progenitor cells. Development 2002, 129:1553-1567.
67. Lobsiger C.S., Cleveland D.W. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat. Neurosci. 2007, 10:1355-1360.
68. Lujan E., Chanda S., Ahlenius H., Südhof T.C., Wernig M. Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells. Proc. Natl. Acad. Sci. USA 2012, 109:2527-2532.
69. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9. Science 2013, 339:823-826.
70. Marchetto M.C., Carromeu C., Acab A., Yu D., Yeo G.W., Mu Y., Chen G., Gage F.H., Muotri A.R. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143:527-539.
71. Marro S., Pang Z.P., Yang N., Tsai M.C., Qu K., Chang H.Y., Südhof T.C., Wernig M. Direct lineage conversion of terminally differentiated hepatocytes to functional neurons. Cell Stem Cell 2011, 9:374-382.
72. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
73. Menendez L., Kulik M.J., Page A.T., Park S.S., Lauderdale J.D., Cunningham M.L., Dalton S. Directed differentiation of human pluripotent cells to neural crest stem cells. Nat. Protoc. 2013, 8:203-212.
74. Mori K., Weng S.M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339:1335-1338.
75. Muñoz-Sanjuán I., Brivanlou A.H. Neural induction, the default model and embryonic stem cells. Nat. Rev. Neurosci. 2002, 3:271-280.
76. Nagai M., Re D.B., Nagata T., Chalazonitis A., Jessell T.M., Wichterle H., Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007, 10:615-622.
77. Nakamura M., Tsuji O., Nori S., Toyama Y., Okano H. Cell transplantation for spinal cord injury focusing on iPSCs. Expert Opin. Biol. Ther. 2012, 12:811-821.
78. Nguyen H.N., Byers B., Cord B., Shcheglovitov A., Byrne J., Gujar P., Kee K., Schüle B., Dolmetsch R.E., Langston W., et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011, 8:267-280.
79. Nieto M., Schuurmans C., Britz O., Guillemot F. Neural bHLH genes control the neuronal versus glial fate decision in cortical progenitors. Neuron 2001, 29:401-413.
80. Okita K., Matsumura Y., Sato Y., Okada A., Morizane A., Okamoto S., Hong H., Nakagawa M., Tanabe K., Tezuka K., et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 2011, 8:409-412.
81. Pang Z.P., Yang N., Vierbuchen T., Ostermeier A., Fuentes D.R., Yang T.Q., Citri A., Sebastiano V., Marro S., Südhof T.C., Wernig M. Induction of human neuronal cells by defined transcription factors. Nature 2011, 476:220-223.
82. Parras C.M., Schuurmans C., Scardigli R., Kim J., Anderson D.J., Guillemot F. Divergent functions of the proneural genes Mash1 and Ngn2 in the specification of neuronal subtype identity. Genes Dev. 2002, 16:324-338.
83. Paşca S.P., Portmann T., Voineagu I., Yazawa M., Shcheglovitov A., Paşca A.M., Cord B., Palmer T.D., Chikahisa S., Nishino S., et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nat. Med. 2011, 17:1657-1662.
84. Pfisterer U., Kirkeby A., Torper O., Wood J., Nelander J., Dufour A., Björklund A., Lindvall O., Jakobsson J., Parmar M. Direct conversion of human fibroblasts to dopaminergic neurons. Proc. Natl. Acad. Sci. USA 2011, 108:10343-10348.
85. Pimplikar S.W., Nixon R.A., Robakis N.K., Shen J., Tsai L.H. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J.Neurosci. 2010, 30:14946-14954.
86. Polymenidou M., Cleveland D.W. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011, 147:498-508.
87. Qiang L., Fujita R., Yamashita T., Angulo S., Rhinn H., Rhee D., Doege C., Chau L., Aubry L., Vanti W.B., et al. Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell 2011, 146:359-371.
88. Rakovic A., Shurkewitsch K., Seibler P., Grünewald A., Zanon A., Hagenah J., Krainc D., Klein C. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J.Biol. Chem. 2013, 288:2223-2237.
89. Reinhardt P., Schmid B., Burbulla L.F., Schöndorf D.C., Wagner L., Glatza M., Höing S., Hargus G., Heck S.A., Dhingra A., et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 2013, 12:354-367.
90. Rhinn H., Qiang L., Yamashita T., Rhee D., Zolin A., Vanti W., Abeliovich A. Alternative α-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. Nat. Commun. 2012, 3:1084.
91. Ring K.L., Tong L.M., Balestra M.E., Javier R., Andrews-Zwilling Y., Li G., Walker D., Zhang W.R., Kreitzer A.C., Huang Y. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012, 11:100-109.
92. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 2007, 39:168-177.
93. Ross S.E., Greenberg M.E., Stiles C.D. Basic helix-loop-helix factors in cortical development. Neuron 2003, 39:13-25.
94. Rouaux C., Arlotta P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons invivo. Nat. Cell Biol. 2013, 15:214-221.
95. Sánchez-Danés A., Richaud-Patin Y., Carballo-Carbajal I., Jiménez-Delgado S., Caig C., Mora S., Di Guglielmo C., Ezquerra M., Patel B., Giralt A., et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 2012, 4:380-395.
96. Schnitzler A.C., Mellott T.J., Lopez-Coviella I., Tallini Y.N., Kotlikoff M.I., Follettie M.T., Blusztajn J.K. BMP9 (bone morphogenetic protein 9) induces NGF as an autocrine/paracrine cholinergic trophic factor in developing basal forebrain neurons. J.Neurosci. 2010, 30:8221-8228.
97. Seibler P., Graziotto J., Jeong H., Simunovic F., Klein C., Krainc D. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J.Neurosci. 2011, 31:5970-5976.
98. Serio A., Bilican B., Barmada S.J., Ando D.M., Zhao C., Siller R., Burr K., Haghi G., Story D., Nishimura A.L., et al. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc. Natl. Acad. Sci. USA 2013, 110:4697-4702.
99. Shimada T., Takai Y., Shinohara K., Yamasaki A., Tominaga-Yoshino K., Ogura A., Toi A., Asano K., Shintani N., Hayata-Takano A., et al. A simplified method to generate serotonergic neurons from mouse embryonic stem and induced pluripotent stem cells. J.Neurochem. 2012, 122:81-93.
100. Soldner F., Laganière J., Cheng A.W., Hockemeyer D., Gao Q., Alagappan R., Khurana V., Golbe L.I., Myers R.H., Lindquist S., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011, 146:318-331.
101. Son E.Y., Ichida J.K., Wainger B.J., Toma J.S., Rafuse V.F., Woolf C.J., Eggan K. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell 2011, 9:205-218.
102. Stadtfeld M., Apostolou E., Akutsu H., Fukuda A., Follett P., Natesan S., Kono T., Shioda T., Hochedlinger K. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010, 465:175-181.
103. Stadtfeld M., Apostolou E., Ferrari F., Choi J., Walsh R.M., Chen T., Ooi S.S., Kim S.Y., Bestor T.H., Shioda T., et al. Ascorbic acid prevents loss of Dlk1-Dio3 imprinting and facilitates generation of all-iPS cell mice from terminally differentiated B cells. Nat. Genet. 2012, 44:398-405. S391-S392.
104. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
105. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
106. Thier M., Wörsdörfer P., Lakes Y.B., Gorris R., Herms S., Opitz T., Seiferling D., Quandel T., Hoffmann P., Nöthen M.M., et al. Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 2012, 10:473-479.
107. Tomazou E.M., Meissner A. Epigenetic regulation of pluripotency. Adv. Exp. Med. Biol. 2010, 695:26-40.
108. Tursun B., Patel T., Kratsios P., Hobert O. Direct conversion of C. elegans germ cells into specific neuron types. Science 2011, 331:304-308.
109. Ullian E.M., Christopherson K.S., Barres B.A. Role for glia in synaptogenesis. Glia 2004, 47:209-216.
110. Vierbuchen T., Ostermeier A., Pang Z.P., Kokubu Y., Südhof T.C., Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463:1035-1041.
111. Wang F., Yin Y., Ye X., Liu K., Zhu H., Wang L., Chiourea M., Okuka M., Ji G., Dan J., et al. Molecular insights into the heterogeneity of telomere reprogramming in induced pluripotent stem cells. Cell Res. 2012, 22:757-768.
112. Warren L., Manos P.D., Ahfeldt T., Loh Y.H., Li H., Lau F., Ebina W., Mandal P.K., Smith Z.D., Meissner A., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7:618-630.
113. Xia G., Santostefano K., Hamazaki T., Liu J., Subramony S.H., Terada N., Ashizawa T. Generation of human-induced pluripotent stem cells to model spinocerebellar ataxia type 2 invitro. J.Mol. Neurosci. 2012, Published online December 9, 2012. 10.1007/s12031-012-9930-2.
114. Xue Y., Ouyang K., Huang J., Zhou Y., Ouyang H., Li H., Wang G., Wu Q., Wei C., Bi Y., et al. Direct conversion of fibroblasts to neurons by reprogramming PTB-regulated microRNA circuits. Cell 2013, 152:82-96.
115. Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., Yoshizaki T., Yamanaka S., Okano H., Suzuki N. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011, 20:4530-4539.
116. Yahata N., Asai M., Kitaoka S., Takahashi K., Asaka I., Hioki H., Kaneko T., Maruyama K., Saido T.C., Nakahata T., et al. Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS ONE 2011, 6:e25788.
117. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007, 1:39-49.
118. Yazawa M., Dolmetsch R.E. Modeling Timothy syndrome with iPS cells. J.Cardiovasc. Transl. Res. 2013, 6:1-9.
119. Yoo A.S., Sun A.X., Li L., Shcheglovitov A., Portmann T., Li Y., Lee-Messer C., Dolmetsch R.E., Tsien R.W., Crabtree G.R. MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 2011, 476:228-231.
120. Zeng H., Guo M., Martins-Taylor K., Wang X., Zhang Z., Park J.W., Zhan S., Kronenberg M.S., Lichtler A., Liu H.X., et al. Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS ONE 2010, 5:e11853.
121. Zhang N., An M.C., Montoro D., Ellerby L.M. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr. 2010, 2:RRN1193.